MGRM Form 4: Director's 7,000 options cancelled, CVR and cash terms outlined
Rhea-AI Filing Summary
Monogram Technologies insider Richard Van Kirk filed a Form 4 showing that 7,000 stock options were cancelled on 10/07/2025 as part of the company’s merger with Zimmer Biomet. Under the merger terms, each outstanding option converted into a cash payment equal to the excess of $4.04 per share over the option’s exercise price plus a contractual contingent value right (CVR) where applicable, or into a CVR alone for options with higher exercise prices; options with exercise prices above $16.41 were cancelled without consideration. The filing is signed by an attorney-in-fact for Mr. Van Kirk and reflects the post-closing treatment of equity awards when the issuer became a wholly owned subsidiary of Zimmer Biomet.
Positive
- 7,000 options converted rather than left outstanding, providing cash consideration to in-the-money holders
- Clear, documented merger treatment reduces future ambiguity about option status for insiders
Negative
- Options with exercise prices above $16.41 were cancelled for no consideration, eliminating potential upside for some holders
- Part of the value is tied to a CVR, creating uncertainty until contingent payments are resolved
Insights
TL;DR: Director options were cancelled and converted under merger terms, affecting insider ownership.
The transaction terminated outstanding options and set a clear cash-and-CVR conversion framework: a $4.04 cash reference plus potential CVR value up to $16.41. This changes the composition of equity awards and reduces direct option holdings for insiders.
The main dependency is the CVR agreement terms and any contingent payments tied to future milestones; until those payoffs are resolved, total economic value remains partly uncertain. Monitor any disclosed CVR payout schedule or trigger events over the next 12–36 months for realization of value.
TL;DR: Cancellation of options alters realized compensation; some optionholders receive cash, others only CVRs or nothing.
The conversion rule distinguishes options by exercise price: in-the-money options received a cash component plus CVR rights, mid-range options received CVRs net of the cash amount, and deeply out-of-the-money options were cancelled for no consideration. That segmentation affects the payback to employees and directors who held options.
Key items to watch are the number of CVRs outstanding, the CVR payment formula, and any vesting/forfeiture conditions that could change payout timing or size within the next 1–3 years.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option | 7,000 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated July 11, 2025 (the "Original Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., ("Zimmer Biomet"), and Honey Badger Merger Sub, Inc., a wholly owned subsidiary of Zimmer Biomet ("Merger Sub"), as amended by that certain First Amendment to Agreement and Plan of Merger, dated August 27, 2025, by and between the Issuer and Zimmer Biomet (together with the Original Merger Agreement, the "Merger Agreement"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Zimmer Biomet upon consummation of the merger (the "Effective Time"). At the Effective Time, each outstanding and unexercised option, whether or not vested, was cancelled and converted into the right to receive, (i) a cash payment equal to the excess of (A) $4.04 (the "Cash Amount") over (B) the exercise price per share of such option, and (ii) one contractual contingent value right issued pursuant to and in accordance with the CVR agreement ("CVR"). However, any such option (1) with a per share exercise price that is equal to or greater than the Cash Amount but less than the sum of the Cash Amount and the maximum CVR consideration payable pursuant to the CVR agreement (that is, $16.41) was cancelled and converted into the right to receive, for each share of common stock underlying such option, one CVR issued pursuant to and in accordance with the CVR agreement less the Cash Amount and (2) with a per share exercise price greater than $16.41 was cancelled for no consideration.
